Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Starts Discussing Blood Law Amendment Focusing on Use of Blood-Derived iPS Cells, New Entrants into Blood Collection
A health ministry panel initiated discussions on amending the Blood Law on April 24. The Ministry of Health, Labor and Welfare (MHLW) cited the use of blood-derived iPS cells in R&D and the participation of new entities in blood collection…
To read the full story
Related Article
- MHLW to Allow Blood Collection for Use of Blood in Drug R&D under Amended Blood Law
June 12, 2020
- MHLW Panel Approves Plan to Amend Blood Law
December 17, 2018
- Council Approves Draft Revision of “Basic Policy on Blood Products”
October 2, 2018
- MHLW to Discuss Measures to Strengthen Governance among Blood Collection Operators through Amendment of Blood Law
September 7, 2018
- EFPIA Japan Proposes Establishing Organization Formed by Multiple Companies for Blood Collection Operation
August 10, 2018
REGULATORY
- MHLW Lifts Olanzapine Diabetes Contraindication for Antiemetic Use
August 26, 2026
- PMDA Flags Severe Gastritis, Esophagitis with Checkpoint Inhibitors
August 26, 2026
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…